Crossject
Created in 2001
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,163 5,653Activities
Technologies
Entity types
Location
6 Rue Pauline Kergomard, 21000 Dijon, France
Dijon
France
Employees
Scale: 51-200
Estimated: 95
Engaged corporates
24
9 4Added in Motherbase
3 years, 7 months ago
deeptech Value proposition
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Injection sans aiguile and Traitements d'urgenceOriginal language
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Crossject | Auto-injection sans aiguille | ZENEO®
Crossject développe un mode d'injection sans aiguille innovant, ZENEO®, plateforme d'injection sans piqûre de solutions médicamenteuses
https://crossject.com/fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Les Docks Numériques IT Services and IT Consulting | Les Docks Numériques IT Services and IT Consulting | Other 16 Jan 2025 | | |
 La French Tech Media, Government Administration | La French Tech Media, Government Administration | Other 15 Jan 2025 | | |
 ADEME National and local authorities, Environmental Services | ADEME National and local authorities, Environmental Services | Other 9 Dec 2024 | | |
 | Ministère de la Défense | Other 21 Oct 2024 | | |
 J.P. Morgan Bank | J.P. Morgan Bank | Other 17 Jan 2025 | | |
 Eurofins Scientifique Biotechnology, Biotechnology Research | Eurofins Scientifique Biotechnology, Biotechnology Research | Other 23 Jul 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 17 May 2024 | | |
 | ANSM Agence nationale de sécurité du médicament et des produits de santé | Other 7 Sep 2023 | | |
 Syneos Health Pharmaceutical, Biotechnology Research | Syneos Health Pharmaceutical, Biotechnology Research | Other 30 Sep 2024 | | |
 | Gouvernement | Other 4 Oct 2023 | | |